Role of Chloroquine and Hydroxychloroquine in the Treatment of COVID-19 Infection-A

Systematic Literature Review

Krishan Mohan Kapoor^{1 2 3}, Aanandita Kapoor⁴

Abstract

Background: Coronavirus pandemic is currently a global public health emergency. At present, no

pharmacological treatment is known to treat this condition, and there is a need to review the available

treatments.

Objective: While there have been studies to describe the role of chloroquine and hydroxychloroquine

in various viral conditions, there is limited information about the use of them in COVID-19. This

systematic review aims to summarize the available evidence regarding the role of chloroquine in

treating coronavirus infection.

Methods: The preferred reporting items for systematic reviews and meta-analyses (PRISMA)

guidelines were used for this review. A literature search was performed using PUBMED & Google

Scholar to find articles about the role of CQ in COVID-19 patients.

Results: We included 19 publications (Five published articles, three letters/correspondence, one

commentary, five pre-proofs of accepted articles, one abstract of yet to be published article, and four

were pre-prints (not yet peer-reviewed) articles) in this systematic review. All the articles mentioned

about the role of chloroquine and /or hydroxychloroquine in limiting the infection with SARS-CoV-2

(the virus causing COVID-19).

Conclusions: There is theoretical, experimental, preclinical and clinical evidence of the effectiveness

of chloroquine in patients affected with COVID-19. There is adequate evidence of drug safety from

the long-time clinical use of chloroquine and hydroxychloroquine in other indications. More data

from ongoing and future trials will add more insight into the role of chloroquine and

hydroxychloroquine in COVID-19 infection.

Keywords: Chloroquine, Hydroxychloroquine, COVID-19, SARS-CoV-2, Coronavirus, SARS, HIV

Introduction

An outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or COVID-19) was reported in Wuhan, China, in December 2019, which spread to the rest of China and many other countries across the globe. Globally the number of people diagnosed with COVID-19 infection is increasing exponentially, and it has been declared a pandemic by WHO. At present, no pharmacological agent has been approved by regulatory agencies for the treatment of SARS-CoV-2 infection, and a review of drugs found to be effective against COVID-19 is the need of the hour. Chloroquine (CQ) has been used extensively as an antimalarial agent with immunomodulatory effects¹ ² ³. A derivative of CQ, Hydroxychloroquine sulfate (HCQ) was synthesized first in 1946 by adding a hydroxyl group to CQ and is much less toxic than CQ in animal studies⁴. CQ has been used in SARS Coronavirus infection due to its antiviral properties⁵ ⁶. Recently CQ has also been found to have Anti-COVID-19 activity in vitro⁷. For these reasons, CQ and HCQ could be the potential drug for treating COVID-19 infection. To date, there is no clinical evidence to support the use of CQ or HCQ for treating SARS-CoV-2 infection though many clinical trials with these drugs are already underway⁸. This study aims to systematically review the available literature for the use of CQ or HCQ in treating COVID-19 infection.

Materials and Methods

A systematic review of the published literature was done to find the role of CQ in COVID 19 infection. The Preferred Reporting Items for Systematic Reviews and Meta-analyses, PRISMA, guidelines were used for the review. The publications selected in this study included the abstracts, original articles, pre-proofs of the accepted article, pre-prints, case reports or case series, letter to editor and experts' opinions, published since inception till 23rd March, 2020, which investigated or

discussed the role of CQ in COVID 19 infection. The articles excluded from this study were duplicate

papers, posters, and papers without the mention of the role of CQ in COVID-19 infection.

Literature search and Data Sources

PubMed and Google Scholar were used for searching the articles, reporting on the topics of the role of

CQ in COVID 19 infection. The search was conducted using the following keywords: "Chloroquine,"

"Hydroxychloroquine," " COVID-19," and "SARS-CoV-2" with a publication time range up to 23rd

March, 2020. The abstract & purpose of the articles found during the literature search were reviewed.

Articles describing the role of CQ or HCQ in COVID-19 infection were selected for full-text review.

Screening

Titles, as well as the abstracts of items in the search results, were screened. The full-text of the

selected articles was downloaded. Relevant information about the use of CQ and HCQ from all the

selected articles was extracted. The data from selected articles were studied independently by two

investigators (KMK and AK), and consensus was achieved with mutual discussion.

Data Extraction and Analysis

The relevant data were extracted from selected articles by two authors (KMK and AK). The data

points were tabulated after reading the full text of each selected article. As the number of the selected

articles was small, the findings were presented in the form of a table & narrative summaries.

Results:

The initial search for the role of chloroquine in Covid-19 yielded 282 entries, published till 23rd

March, 2020. After using the exclusion criteria, eighteen items were selected. The list included five

published articles ⁹ ¹⁰ ¹¹ ¹² ¹³, three letters/correspondence ¹⁴ ¹⁵ ⁷, one commentary ¹⁶, four pre-proofs of

accepted articles 17 18 19 20 21, one abstract of yet to be published article 22 and four w pre-prints (not yet

peer-reviewed) articles²³ ²⁴ ²⁵ ⁸. One publication in Chinese¹³ was selected after a review of the English abstract, and it was translated in the English language using Google Translator service.

Discussion

Chloroquine (CQ) is a well-known 4-aminoquinoline that has been in clinical use since 1944. Hydroxychloroquine sulfate (HCQ) was synthesized in 1946 with the addition of a hydroxyl group to CQ. CQ has been used extensively in treating malaria and also for the treatment of autoimmune disorders such as rheumatoid arthritis, systemic lupus erythematosus, etc. because of its immunomodulatory role²⁶ ²⁷.

CQ exerts its antiviral effects through various mechanisms in the cell. CQ is weakly alkaline in nature, and it can change the pH of endosomes. Thus it can exert a significant inhibitory effect on viral infections, which invade cells via the endosome pathway like Zika virus²⁸ and Borna disease virus³⁰.

Many other viruses like Ebola (EBOV) depend on the naturally low pH of acidic endosomes for activating and triggering the fusion by their envelope glycoproteins. Thus a 'fusion inhibitor' could target the host cell machinery by preventing the acidification of the endosome to inhibit virus entry. The cell entry by EBOV, FLU-H5, and MARV can be inhibited due to the increase in the endosome pH by CQ due to its ability to prevent the acidification of intracellular organelles³¹.

The data on the kinetics of chloroquine uptake indicated the drug attained near-maximum intracellular concentrations in 1 hr and a drug level of $60 \mu g/ml$ produced a decrement in the cellular biosynthesis of protein, RNA, or DNA. Herpes simplex replication was found to be sensitive to this drug as the level of progeny virus production was depressed by 95% in 24 hr.³²

CQ also affects viral replication by inhibiting viral gene expression. CQ has an ability to change the pattern of glycosylation in HIV-1 gp120 envelope during In vitro and in vivo tests. CQ also inhibits the replication of the HIV virus in CD4 + T cells³³. Both CQ and HCQ are weakly alkaline bases and

affect the acid vesicles causing the dysfunction of enzymes required for post-translational protein modifications. These drugs increase the pH of acidic vesicles, cause disruption of several enzymes like acid hydrolases & lead to inhibition of the post-transcriptional modification of newly synthesized proteins. The mechanisms thought to explain the anti-HIV-1 effect of CQ and HCQ include: alteration in gp120 production, restriction of intracellular iron (a cofactor) necessary for HIV-1 replication, an effect on Tat-mediated transactivation of the HIV-1 LTR, and the effect on the HIV-1

During animal testing, CQ was also found to effectively inhibit autophagy in the lungs of avian influenza H5N1 mice and reduce alveolar epithelial damage. CQ could efficiently ameliorate the acute lung injury and significantly improve the survival rate in mice infected with live avian influenza A H5N1 virus.³⁵

integrase.34

Coronaviruses are enveloped viruses having non-segmented, single-stranded & positive-sense RNA genomes. Apart from causing infections in vertebrates in the meat industry like pigs and chickens, until recently, six coronaviruses are known to infect human hosts & cause respiratory diseases. COVID-19 is the latest addition to this family of viruses. Among these, severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly pathogenic coronaviruses which have resulted in regional and global outbreaks. Currently, there are no clinically specific pharmacologic agents for these seven coronaviruses.

CQ has been found to cause inhibition of the replication of SARS-CoV in Vero E6 cells. The IC_{50} of chloroquine inhibition of SARS-CoV replication in Vero E6 cells, 8.8 μ M, is 1000-fold below the human plasma concentrations of CQ, reached following acute malaria treatment with chloroquine at a dose of 25 mg/kg over three days. The dose of chloroquine used for the treatment of rheumatoid arthritis (3.6 mg/kg) was found to produce plasma CQ concentrations of 1–3 μ M, which is in the same concentration range as the IC_{50} for inhibition of SARS-CoV.³⁷ ³⁸

CQ has been found to be effective in inhibiting the infection and spread of SARS CoV in cell culture.

CQ inhibits the virus replication by reducing the terminal glycosylation of angiotensin-converting

enzyme 2 (ACE2) receptors on the Vero E6 cells' surface and interfering with the binding of SARS-

CoV to the ACE2 receptors. CQ had a significant inhibitory antiviral effect when the susceptible cells

were treated either before or after infection, suggesting a possible prophylactic and therapeutic use.⁵

CQ interferes with COVID-19's attempt to acidify the lysosomes & probably inhibits cathepsins,

which needs a low pH for optimal cleavage of COVID-19 spike protein, a requirement for the

formation of the autophagosome.¹⁸

The Wuhan CoV (COVID-19) S-protein shares an almost identical 3-D structure in its RBD domain

with SARS-CoV S-protein. Although relatively weaker than SARS-CoV, the Wuhan CoV S-protein

has a strong binding affinity to human ACE2 receptors. Hence, the Wuhan CoV poses a significant

risk for human transmission due to the S- protein-ACE2 binding pathway like SARS-CoV. 20 39

CQ has been found to function at both entry as well as post-entry stages of the COVID-19 infection in

Vero E6 cells. The immune-modulating activity of CQ may also synergistically enhance its antiviral

effect in vivo. After oral intake, CQ gets widely distributed in the whole body, including lung. The

EC90 value of chloroquine against the COVID-19 in Vero E6 cells was 6.90μM, which is achievable

clinically, as shown in the plasma of rheumatoid arthritis patients receiving 500 mg daily dose⁷. The

low cost and good safety profile makes CQ a potentially clinically applicable drug against the

COVID-19 infection.⁷

The endemic malaria presence seems to protect certain populations from COVID-19 infection,

especially in the least developed countries. The mechanism of action of some antimalarial drugs with

antiviral property suggests their potential role in the chemoprophylaxis of the COVID-19 epidemic.²²

In a study, CQ has been found out to be the potential inhibitor of viral PLpro. The effect of

chloroquine during post-entry stages could be manifested via its inhibition of the crucial viral protein,

PLpro.²³

The suggested regimen by Dutch CDC in adults includes an initial dose of 600 mg of chloroquine base followed by 300 mg after 12 h on the first day, followed by 300 mg twice daily on days second to fifth. This document also emphasizes the need for stopping the treatment at day 5 to reduce the risk of side effects, as CQ has a long half-life of 30 hours. There is also a need to differentiate between treatment based on chloroquine phosphate and chloroquine base since 500 mg of chloroquine phosphate is equivalent to 300 mg of chloroquine base. Another set of guidelines by the Italian Society of Infectious and Tropical disease (Lombardy section) suggests the use of CQ 500 mg twice daily or HCQ 200 mg once daily for ten days with treatment duration varying between 5 to 20 days based on clinical severity. The suggested target group of patients ranged from patients with mild respiratory symptoms having comorbidities to patients with severe respiratory failure.¹¹

CQ has been recommended for 18–65 years of COVID-19 infected adults at a dose of 500mg twice daily for seven days. For BW \leq 50 kg patients, the CQ dose should be decreased to 500 once daily during day third to seventh of the treatment cycle (Table 1). There has been no dose recommendation of CQ in COVID-19 infected children so far; hence extreme caution should be followed while prescribing it for children. Acute poisoning of CQ is usually fatal with a dose of 50 mg/kg, and CQ concentration > 25 μ mol/L is a fatal predictor. In Nigerian children with acute uncomplicated malaria, chloroquine absorption appeared reliable as peak chloroquine concentrations were achieved within 0.5 hours, and its concentration decline slowly, with an elimination half-life of 20 to 60 days. CQ can be detected in urine months after a single dose.

In accordance with the "New Coronavirus Pneumonia Diagnosis and Treatment Program (Trial Version 6)" issued by the National Health and Health Commission in China, the recommended dosage of Chloroquine phosphate tablets is 500 mg BID daily for ten days⁹. In case of severe gastrointestinal symptoms, the dose of CQ can be reduced to 500 mg once daily, or can even be discontinued. During the course of CQ treatment, if the throat swab becomes negative and stays negative for three days, the drug withdrawal can be considered. However, the minimum course of CQ treatment needs to be at least five days¹³.

So far, results of more than 100 patients treated with CQ has shown that chloroquine phosphate is superior to the control treatment as it inhibits the worsening of pneumonia, improves the lung imaging findings, promotes a virus-negative conversion, and shortens the course of the disease. Severe adverse reactions to CQ were not seen in these patients. The drug has been recommended for inclusion in the next version of the Guidelines for the Prevention, Diagnosis, and Treatment of Pneumonia Caused by COVID-19, issued by the National Health Commission of the People's Republic of China. This would be the first successful use of CQ in humans for treating acute viral disease. However, this information should be carefully considered before drawing any definitive conclusion as no supporting clinical data has been released yet.

As of 23rd February 2020, seven clinical trial registries have been found in the Chinese Clinical Trial Registry for using HCQ to COVID-19 treatment. It has been reported that the safe dosage of HCQ (6–6.5 mg/kg per day) could reach serum levels of 1.4–1.5 μM in humans. In animals, CQ and HCQ share similar tissue distribution, with concentrations in the liver, spleen, kidney, and lung reaching levels, which are 200–700 times higher than those in the plasma. Therefore a very high concentration in the above tissues is likely to be achieved with the safe dosage of HCQ for inhibiting SARS-CoV-2 infection. This possibility, however, awaits confirmation by clinical trials. In patients with COVID-19 infection, CQ can interact with lopinavir/ritonavir, Causing QT interval prolongation. Hence HCQ can be considered instead of CQ when the latter is not available for COVID-19 treatment.

HCQ has been found to be more potent than CQ at inhibiting SARS-CoV-2 *in vitro*. HCQ Sulfate 400 mg twice daily for one day, followed by 200 mg twice daily for four more days, has been recommended for treating COVID-19 infection.¹⁹ Based on CQ's antiviral mechanisms, its laboratory activity against COVID-19, as well as CQ's pharmacokinetics based on its use for malaria and autoimmune diseases, safe and potentially efficacious dose regimens have been recommended for protection against COVID-19. This protocol has pre-exposure prophylaxis of 250-500mg CQ daily and post-exposure prophylaxis at 8mg/kg/day CQ for three days.²⁴

In a recent trial using HCQ as a single drug and HCQ in combination with azithromycin, the

proportion of patients with negative PCR results in nasopharyngeal samples had a significant

difference between the two groups. At day six post-treatment, 100% of patients treated with HCQ and

azithromycin combination had been virologically cured compared to 57.1% in patients treated with

only HCQ and 12.5% in control group.²¹

Contraindications and relative contraindications include NOT to use CQ in people below 18 years and

above 65 years, pregnant women, persons allergic to 4-aminoquinoline, patients with hematological

disorders or G6PD deficiency, patients with chronic liver or kidney disease, patients with arrhythmia

and chronic heart disease, patients with a history of retinal disease or hearing loss, patients known to

have a mental illness, Skin diseases like a rash, dermatitis, psoriasis. CQ is known to have drug

interactions with various drugs, and expert medical opinion, regarding its interaction with the

medicines already taken by patients, is a MUST.

There are some mild side effects of CQ while treating malaria, including headache, dizziness, loss of

appetite, etc. The primary adverse reaction of CQ at higher doses is ocular toxicity, which could

affect the vision. If the discomfort in the eye or visual abnormality occurs, CQ should be discontinued

immediately. Other side effects of CQ include cardiac arrhythmia, drug-induced psychosis,

leukopenia, etc. Combining CQ with heparin could increase the risk of bleeding. In patients taking

Digitalis, CQ could cause a cardiac block.¹³

For decades, most Europeans visiting malaria-endemic areas have been receiving chloroquine

prophylaxis, and they would continue it for two months after their return. The use of CQ for the

treatment of malaria has also been in use for long, and HCQ has been used at much higher doses of up

to 600 mg/day to treat autoimmune diseases. It is quite difficult to find a product having a better-

established safety profile than CQ at such a low cost. 10 CQ, and its derivatives have shown early

promise to treat COVID-19 infection and should be explored as a potential drug in the preventive and

therapeutic role to turn the tide in this rapidly evolving pandemic.²⁵ Disorderly clinical trials of

COVID-19 using traditional Chinese medicine and Western medicine are ongoing but may not be able

to give high-quality clinical evidence. In order to death with the health emergency create by COVID-

19, the national administration of scientific research should improve management and coordination

for improving the study quality based on clinical trial guidelines.⁸

It is also recommended to further research on the role of CQ for COVID-19 prevention. It has also

been urged in an article that the above CQ regimens be investigated in parallel with the mass

deployment of this drug, without unnecessary regulatory delays, in an attempt to contain the global

pandemic as the benefits of CQ far outweigh the risks or costs. 24

Conclusions

The results of in vitro studies and those of recent clinical trials using CQ and HCQ in COVID-19

infection are quite promising. An international strategy for allowing the use of promising drugs like

CQ and HCQ for COVID-19 should be made. Considering the low cost, easy availability, and

minimal adverse effects, CQ and HCQ should be prescribed to COVID-19 patients under medical

supervision. Further trials with this drug will throw more light on its usefulness in COVID-19

infection.

Limitations

This systematic review had some limitations, including a small sample size of publications and

limited data regarding the role of CQ and HCQ in human infection with COVID-19. However, under

current emergency circumstances, we believe our study will be beneficial to the scientific community

and the general public.

Declaration of Competing Interest

N/A

Funding

No Funding received

Ethical Approval

Not needed

Abbreviations: CQ- Chloroquine, CQP- Chloroquine phosphate, HCQ- Hydroxychloroquine, PRISMA- preferred reporting items for systematic reviews and meta-analyses

Bibliography

- Cooper RG, Magwere T. Chloroquine: Novel uses & manifestations. *Indian J Med Res*.
 2008;127(4):305-316.
- Sharma VP. Battling the malaria iceberg with chloroquine in India. Malar J. 2007;6(1):105. doi:10.1186/1475-2875-6-105
- 3. Ansah EK, Gyapong JO, Agyepong IA, Evans DB. Improving adherence to malaria treatment for children: the use of pre-packed chloroquine tablets vs. chloroquine syrup. *Trop Med Int Heal*. 2001;6(7):496-504. doi:10.1046/j.1365-3156.2001.00740.x
- 4. McChesney EW. Animal toxicity and pharmacokinetics of hydroxychloroquine sulfate. *Am J Med.* 1983;75(1A):11-18. doi:10.1016/0002-9343(83)91265-2
- Vincent MJ, Bergeron E, Benjannet S, et al. chloroquine is a potent inhibitor of SARS coronavirus infection and spread. *Virol J.* 2005;2(69):1-10. doi:10.1186/1743-422X-2-69
- Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? *Lancet Infect Dis*. 2003;3(11):722-727. doi:10.1016/s1473-3099(03)00806-5
- Wang M et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res.* 2020;30(January):269-271. doi:10.1038/s41422-020-0282-0
- 8. Zhu R, Gao R, Robert S-H, Gao J, Yang S, Zhu C. Systematic Review of the Registered Clinical Trials of Coronavirus Disease 2019 (COVID-19). *medRxiv*. January 2020:2020.03.01.20029611. doi:10.1101/2020.03.01.20029611

- 9. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther*. 2020;14(1):58-60. doi:10.5582/ddt.2020.01012
- 10. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. *Int J Antimicrob Agents*. 2020;55(3):105923. doi:10.1016/j.ijantimicag.2020.105923
- Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care*. 2020:3-7. doi:10.1016/J.JCRC.2020.03.005
- Wang Y, Zhu L-Q. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. World J Pediatr. 2020;(0123456789):20-23. doi:10.1007/s12519-020-00353-5
- 13. Mingxing H et al. [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. *Zhonghua jie he he hu xi za zhi (Chinese J Tuberc Respir Dis.* 2020;43(3):185-188. doi:10.3760/cma.j.issn.1001-0939.2020.03.009
- 14. Gao J, Tian Z, Yang X. Breakthrough □: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. *Biosci Trends*. 2020:1-2. doi:10.5582/bst.2020.01047
- Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. *Cell Discov*. 2020:6-9. doi:10.1038/s41421-020-0156-0
- Touret F, de Lamballerie X. Of chloroquine and COVID-19. *Antiviral Res*.
 2020;177(February):104762. doi:10.1016/j.antiviral.2020.104762
- Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines Against Coronavirus Disease
 2019 (COVID-19): Chloroquine or Hydroxychloroquine. *Int J Antimicrob Agents*.
 2020;2019:105945. doi:10.1016/j.ijantimicag.2020.105945
- Devaux CA, Rolain J, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? *Int J Antimicrob Agents*. 2020:105938. doi:10.1016/j.ijantimicag.2020.105938
- 19. Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing

- Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clin Infect Dis.* March 2020. doi:10.1093/cid/ciaa237
- Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J Med Virol. 2020:0-2. doi:10.1002/jmv.25707
- Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*.
 2020:105949. doi:https://doi.org/10.1016/j.ijantimicag.2020.105949
- 22. Nioi, M; Napoli P. Global Spread of Coronavirus Disease 2019 and Malaria; An epidemiological paradox. *SSRN*. 2020. doi:https://dx.doi.org/10.2139/ssrn.3554389
- Arya R, Das A, Prashar V, Kumar M. Potential inhibitors against papain-like protease of novel coronavirus (SARS-CoV-2) from FDA approved drugs. *ChemrxivOrg*. 2020;(February 2020). doi:10.26434/chemrxiv.11860011.v2
- Chang R, Sun W-Z. Repositioning Chloroquine as Ideal Antiviral Prophylactic against
 COVID-19 Time is Now. March 2020. doi:10.20944/PREPRINTS202003.0279.V1
- Kearney J. Chloroquine as a Potential Treatment and Prevention Measure for the 2019 Novel
 Coronavirus: A Review. *Pre-prints*. March 2020. doi:10.20944/PREPRINTS202003.0275.V1
- Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. *Nat Rev Rheumatol*. 2020;16(3):155-166. doi:10.1038/s41584-020-0372-x
- Plantone D, Koudriavtseva T. Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. Clin Drug Investig. 2018;38(8):653-671. doi:10.1007/s40261-018-0656-y
- 28. Delvecchio R, Higa LM, Pezzuto P, et al. Chloroquine, an endocytosis blocking agent, inhibits zika virus infection in different cell models. *Viruses*. 2016;8(12):1-15. doi:10.3390/v8120322
- Zhang S, Yi C, Li C, et al. chloroquine inhibits endosomal viral RNA release and autophagydependent viral replication and effectively prevents maternal to fetal transmission of Zika virus. *Antiviral Res.* 2019;169(190):104547. doi:10.1016/j.antiviral.2019.104547
- 30. Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral

- infections that emerge or emerged from viruses requiring an acidic pH for infectivity. *Cell Biochem Funct*. 2016;34(4):191-196. doi:10.1002/cbf.3182
- Long J, Wright E, Molesti E, Temperton N, Barclay W. Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry. F1000Research. 2015;4:30. doi:10.12688/f1000research.6085.2
- Lancz GJ, McLaren LC, James CG, Scaletti J V. Chloroquine mediated alterations in mammalian cell metabolism and viral replication. *Proc Soc Exp Biol Med.* 1971;136(4):1289-1293. doi:10.3181/00379727-136-35477
- 33. Naarding MA, Baan E, Pollakis G, Paxton WA. Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGN mediated transfer of virus to CD4+T-lymphocytes.

 *Retrovirology. 2007;4(1):6. doi:10.1186/1742-4690-4-6
- 34. Savarino A, Gennero L, Sperber K, Boelaert JR. The anti-HIV-1 activity of chloroquine. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2001;20(3):131-135. doi:10.1016/s1386-6532(00)00139-6
- 35. Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. *Cell Res.* 2013;23(2):300-302. doi:10.1038/cr.2012.165
- Fung TS, Liu DX. Human Coronavirus: Host-Pathogen Interaction. *Annu Rev Microbiol*.
 2019;73(1):529-557. doi:10.1146/annurev-micro-020518-115759
- 37. Charmot G, Coulaud JP. [Treatment of Plasmodium falciparum malaria in Africa (except cerebral malaria)]. *Med Trop (Mars)*. 1990;50(1):103-108.
- 38. Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst M Van. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. 2004;323:264-268. doi:10.1016/j.bbrc.2004.08.085
- 39. Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Sci China Life Sci*. 2020;63(3):457-460. doi:10.1007/s11427-020-1637-5
- 40. Ducharme J, Farinotti R. Clinical Pharmacokinetics and Metabolism of Chloroquine Focus on

Recent Advancements. 1996;31(4):257-274.

Table1: Recommendations in various publications about the role of CQ and HCQ in COVID-19 Infection

No	Reference	Dose Recommendation	Duration	Special comment
1	Dong et al ⁹	CQP 500mg BID daily	Not more than	For treatment
		(CQ 300 mg BID) daily	ten days	
2	Colson et al ¹⁰	NA	NA	For treatment and
				prophylaxis
3a	Cortegiani et al ¹¹	CQ 600mg stat+ 300mg after 12 hrs on day 1,	Not more than	For treatment
		followed by 300mg x2/ day from day 2-5 (as per	five days	
		Dutch CDC)		
3b	Cortegiani et al ¹¹	CQP 500mg twice daily for ten days	5-20 days	For Treatment
		HCP 200mg daily for ten days (as per Italian		
		Society of Infectious and Tropical disease)		
4	Wang Y, et al ¹²	CQP 500mg twice daily for seven days	Seven days	50mg/kg is a fatal dose
		No dose recommendation for Children		
		For BW<50kg, CQP 500mg per day		
5	Mingxing H, et al ¹³	CQP 500mg twice daily for ten days	Minimum 5	Reduce to 500mg once
			days	daily or discontinue if GI
				symptoms
6	Gao J, et al ¹⁴	NA	NA	CP inhibits the worsening
				of pneumonia, improves
				lung imaging findings,
				promotes a virus-negative
				conversion, and shortens
				the disease course
7	Liu J, et al ¹⁵	NA	NA	Safe daily dosage (6–6.5
				mg/kg) of HCQ could get
				serum levels of 1.4–1.5
				μM in humans

against the 2019-rtCoV in VeroE6 cells was 6.90µM, achieved clinically with S00 mg daily in RA patients 9 Touret et al. NA NA To wait for interim results of ongoing trials in china of ongoing trials in china of ongoing trials in china consider HCQ instead of CQ when the latter is not available for treating patients with COVID-19. 11 Devanx et al. NA NA CQ interferes with SARS-Co-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-Co-2 spike protein acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-Co-2 spike protein mg twice daily on day 2-5 12 Yao X et al. NA NA NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al. NA NA NA endemic presence of malaria seems to protect some populations from COVID-19 outbreak	8	Wang M, et al ⁷	NA	NA	The EC90 value of CQ
achieved clinically with 500 mg daily in RA patients Patients NA NA To wait for interim results of ongoing trials in china consider HCQ instead of CQ when the latter is not available for treating patients with COVID-19. Devaux et al ¹⁸ NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein HCQ 400 mg twice daily on day 1 followed by 200 Five days MCQ reaches three times the potency of CQP dose of 500 mg BID daily for five days Thought Let al ³⁰ NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor NA NA endemic presence of madaria seems to protect some populations from					against the 2019-nCoV in
9 Touret et al ¹⁶ NA 10 Sahraci Z et al ¹⁷ HCQ 5mg/kg actual body weight 11 Devaux et al ¹⁸ NA NA NA NA NA NA To wait for interim results of ongoing trials in china consider HCQ instead of CQ when the latter is not available for treating patients with COVID-19. 11 Devaux et al ¹⁸ NA NA NA CQ interferes with SARS-CoV-2 attempt to acidify the lyssomethy inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein mg twice daily on day 2-5 Type Actual of CQ interferes with SARS-CoV-2 spike protein mg twice daily on day 2-5 NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor NA NA NA NA NA NA NA NA NA N					VeroE6 cells was 6.90μM,
9 Touret et al ¹⁶ NA NA To wait for interim results of ongoing trials in china consider IICQ instead of CQ when the latter is not available for treating patients with COVID-19. 11 Devaux et al ¹⁸ NA NA NA NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 mg twice daily on day 2-5 The days The					achieved clinically with
9 Touret et al. NA To wait for interim results of ongoing trials in china consider HCQ instead of CQ when the latter is not available for treating patients with COVID-19. 11 Devaux et al. NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al. HCQ 400 mg twice daily on day 1 followed by 200 Five days 13 Zhang L et al. NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al. NA NA endemic presence of malaria seems to protect some populations from					500 mg daily in RA
of ongoing trials in china 10 Sahraei Z et al ¹⁷ HCQ 5mg/kg actual body weight NA consider HCQ instead of CQ when the latter is not available for treating patients with COVID-19. 11 Devaux et al ¹⁸ NA NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days HCQ reaches three times the potency of CQP dose of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA endemic presence of malaria seems to protect some populations from					patients
10 Sahraei Z et al ¹⁵ HCQ 5mg/kg actual body weight NA consider HCQ instead of CQ when the latter is not available for treating patients with COVID-19. NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days HCQ reaches three times the potency of CQP dose of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA endemic presence of malaria seems to protect some populations from	9	Touret et al ¹⁶	NA	NA	To wait for interim results
CQ when the latter is not available for treating patients with COVID-19. 11 Devaux et al ¹⁸ NA NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 mg twice daily on day 2-5 HCQ reaches three times the potency of CQP dose of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from					of ongoing trials in china
available for treating patients with COVID-19. 11 Devaux et al ¹⁸ NA NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 mg twice daily on day 2-5 mg twice daily on day 2-5 NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from	10	Sahraei Z et al ¹⁷	HCQ 5mg/kg actual body weight	NA	consider HCQ instead of
patients with COVID-19. 11 Devaux et al ¹⁸ NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days HCQ reaches three times the potency of CQP dose of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from					CQ when the latter is not
11 Devaux et al ¹⁸ NA CQ interferes with SARS-CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days HCQ reaches three times the potency of CQP dose of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from					available for treating
CoV-2 attempt to acidify the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days mg twice daily on day 2-5 The potency of CQP dose of 500 mg BID daily for five days I3 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor NA NA NA NA endemic presence of malaria seems to protect some populations from					patients with COVID-19.
the lysosomes and presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days mg twice daily on day 2-5 the potency of CQP dose of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA endemic presence of malaria seems to protect some populations from	11	Devaux et al ¹⁸	NA	NA	CQ interferes with SARS-
presumably inhibits cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 mg twice daily on day 2-5 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from					CoV-2 attempt to acidify
cathepsins, which require a low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days mg twice daily on day 2-5 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from					the lysosomes and
low pH for optimal cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor NA NA NA endemic presence of malaria seems to protect some populations from					presumably inhibits
cleavage of SARS-CoV-2 spike protein 12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days the potency of CQP dose of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from					cathepsins, which require a
spike protein HCQ 400 mg twice daily on day 1 followed by 200 Five days HCQ reaches three times the potency of CQP dose of 500 mg BID daily for five days NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor NA NA NA NA endemic presence of malaria seems to protect some populations from					low pH for optimal
12 Yao X et al ¹⁹ HCQ 400 mg twice daily on day 1 followed by 200 Five days the potency of CQP dose of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from					cleavage of SARS-CoV-2
mg twice daily on day 2-5 the potency of CQP dose of 500 mg BID daily for five days NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor NA NA NA endemic presence of malaria seems to protect some populations from					spike protein
of 500 mg BID daily for five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA NA endemic presence of malaria seems to protect some populations from	12	Yao X et al ¹⁹	HCQ 400 mg twice daily on day 1 followed by 200	Five days	HCQ reaches three times
five days 13 Zhang L et al ²⁰ NA NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA endemic presence of malaria seems to protect some populations from			mg twice daily on day 2-5		the potency of CQP dose
NA CQ is a potent inhibitor of SARS coronavirus infection through interfering with ACE2 receptor NA NA endemic presence of malaria seems to protect some populations from					of 500 mg BID daily for
SARS coronavirus infection through interfering with ACE2 receptor 14 Nioi M et al ²² NA NA endemic presence of malaria seems to protect some populations from					five days
infection through interfering with ACE2 receptor NA NA endemic presence of malaria seems to protect some populations from	13	Zhang L et al ²⁰	NA	NA	CQ is a potent inhibitor of
interfering with ACE2 receptor NA Noi M et al ²² NA NA endemic presence of malaria seems to protect some populations from					SARS coronavirus
receptor 14 Nioi M et al ²² NA NA endemic presence of malaria seems to protect some populations from					infection through
14 Nioi M et al ²² NA NA endemic presence of malaria seems to protect some populations from					interfering with ACE2
malaria seems to protect some populations from					receptor
some populations from	14	Nioi M et al ²²	NA	NA	endemic presence of
					malaria seems to protect
COVID-19 outbreak					some populations from
					COVID-19 outbreak

15	Arya R et al ²³	NA	NA	CQ inhibitor of the crucial
				viral protein, PLpro.
16a	Chang R et al ²⁴	CQ 8mg/kg/day for three days in post-exposure but	Three days	-
		asymptomatic cases, ideally to be taken within hours		
		after known viral exposure bas		
16b	Chang R et al ²⁴	CQP 500mg a day as chronic prophylaxis for people	Till the risk of	-
		in outbreak locales or endemic areas with a high risk	infection	
		of exposure, to reduce to 250mg a day after 30 days		
		to continue until the threat of infection is abated.		
17	Kearney J ²⁵	NA	NA	CQ and its derivatives
				have the potential for use
				in the preventive and
				therapeutic role in treating
				SARS-CoV-2
18	Zhu R et al ⁸	NA	NA	Improving the quality of
				study design, prioritizing
				promising drugs, and using
				different designs and
				statistical methods needed
19	Gautret P et al ²¹	HCQ Sulfate 200mg thrice daily for ten days	Ten days	100% viral load reduction
				in 6 days with HCQ +
				Azithromycin
				Combination